Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA clears software that quantifies amyloid in Alzheimer's

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at longevity.technology →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

The FDA granted 510(k) clearance to Cortechs.ai's NeuroQuant PET software, which automates and standardizes amyloid quantification in PET scans for Alzheimer's diagnosis, improving consistency and aiding early treatment decisions.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ ◆ The Wire takeaway

You must align your Alzheimer’s diagnostic tools to standardized quantification now that FDA approval enforces consistent amyloid measurement. Expect payers and prescribers to require numeric biomarkers before approving treatments.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-clearancealzheimerai-diagnosticspet-scanquantification